PMD forms part of MassMEDIC 2023 IGNITE Cohort

Posted by PMD Solutions on Aug 17, 2023 3:09:29 PM

The Massachusetts Medical Device Industry Council (MassMEDIC) is proud to announce the 2023 cohort of the MedTech IGNITE Program (IGNITE), an accelerator program for medtech entrepreneurs, designed and supported by the medtech industry. IGNITE offers a robust calendar of workshops and networking opportunities in a newly-redesigned intensive 3-month program that runs from September – November 2023.

The Medtech IGNITE 2023 cohort includes PMD Solutions:

  • PMD Solutions is the maker of RespiraSense. RespiraSense transforms the measurement of a patient’s Respiratory Rate with continuous, innovative, technology monitoring – improving the measurement and identification of deterioration, in a real-time manner to help save lives.
With the support of sponsors Alira Health, Boyd Technologies, Agile Search, Wilson Sonsini, Teijin Pharma and the Massachusetts Life Sciences Center (MLSC), IGNITE offers founders mentorship from leaders of the largest medtech organizations in New England, experiential training, and investor introductions, all 100% free of charge.  

“The Medtech IGNITE Program accelerates the founder’s journey during the most vulnerable stage of their company’s lifecycle,” said Chief Operating Officer of MassMEDIC and President of Medtech IGNITE, Rachel Robinson. “IGNITE continues to be the premier accelerator focused on development and support of the medtech start-up community in Massachusetts. With the goal of attracting and nurturing the next generation of Boston-area medtech founders and entrepreneurs, we are creating a pipeline of medtech startups who will help fuel the future of the Commonwealth’s medtech ecosystem by establishing offices, hiring teams, and engaging with the MassMEDIC community.”

55 medtech startups have completed the IGNITE Program since it was relaunched in 2019 through a grant from the MLSC. Funding raised by IGNITE companies reached over $150M this year, attracting startups from across the Commonwealth, the U.S. and globally.

To learn more about the 2023 cohort and MassMEDIC, visit:

Recent Posts